Darwin Global Management, Ltd.
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Darwin Global Management, Ltd. reported 12 stock positions worth $751.2 million. Its top holding was Vaxcyte (PCVX) at 25.0% of the portfolio, followed by Nuvalent Class A (NUVL, 14.4%) and Keros Therapeutics (KROS, 12.7%). Compared with Q4 2023, it opened 9 new positions, sold out of 5 and added to 3. The biggest buy was Vaxcyte (PCVX, shares +374%) and the biggest sale an exit from New Ambrx Biopharma (AMAM).
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001839209
- Portfolio Value
- $751.2M (Q1 2024)
- SEC Filing
- 0001892688-24-000066 ↗ filed May 15, 2024
Holdings Value
Holdings 12 stocks · $751.2M
| PCVX Vaxcyte Inc. | 25.02% | 2,750,804 | $187.9M | Add +374.3% |
| NUVL Nuvalent Inc. Class A | 14.36% | 1,436,964 | $107.9M | Add +2390.5% |
| KROS Keros Therapeutics Inc. | 12.65% | 1,435,950 | $95.1M | Add +35.4% |
| BHVN Biohaven Ltd. | 10.75% | 1,476,974 | $80.8M | New |
| ALPN Alpine Immune Sciences Inc. | 10.46% | 1,982,016 | $78.6M | New |
| BEAM Beam Therapeutics Inc. | 9.32% | 2,119,598 | $70.0M | New |
| APGE Apogee Therapeutics Inc. | 7.36% | 832,198 | $55.3M | New |
| XNCR Xencor Inc. | 3.27% | 1,109,650 | $24.6M | New |
| SYRE Spyre Therapeutics Inc. | 2.39% | 473,200 | $17.9M | New |
| ELEV Elevation Oncology Inc. | 1.59% | 2,332,928 | $12.0M | New |
| TRML Tourmaline Bio Inc. | 1.42% | 465,000 | $10.6M | New |
| MRK Merck & Co. Inc. | 1.40% | 79,600 | $10.5M | New |
Portfolio Sells Q4 2023 → Q1 2024
Portfolio Buys Q4 2023 → Q1 2024
| PCVX Vaxcyte Inc. | Add +374.3% | 25.02% | +17.87 |
| NUVL Nuvalent Inc. Class A | Add +2390.5% | 14.36% | +13.53 |
| BHVN Biohaven Ltd. | New | 10.75% | +10.75 |
| ALPN Alpine Immune Sciences Inc. | New | 10.46% | +10.46 |
| BEAM Beam Therapeutics Inc. | New | 9.32% | +9.32 |
| APGE Apogee Therapeutics Inc. | New | 7.36% | +7.36 |
| KROS Keros Therapeutics Inc. | Add +35.4% | 12.65% | +4.38 |
| XNCR Xencor Inc. | New | 3.27% | +3.27 |
| SYRE Spyre Therapeutics Inc. | New | 2.39% | +2.39 |
| ELEV Elevation Oncology Inc. | New | 1.59% | +1.59 |
| TRML Tourmaline Bio Inc. | New | 1.42% | +1.42 |
| MRK Merck & Co. Inc. | New | 1.40% | +1.40 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $3.8B | RVMD, INSM, BLTE, ABVX, ROIV |
| Q1 2026 | 6 | $3.8B | INSM, BLTE, ABVX, RVMD, ROIV |
| Q4 2025 | 6 | $4.9B | INSM, BLTE, ABVX, CDTX, WVE |
| Q3 2025 | 5 | $3.6B | INSM, UTHR, ABVX, CDTX, QURE |
| Q2 2025 | 5 | $2.4B | INSM, VRNA, CDTX, MRUS, ALLO |
| Q1 2025 | 3 | $1.5B | INSM, VRNA, ALLO |
| Q4 2024 | 6 | $1.1B | INSM, JAZZ, VRNA, GERN, KROS |
| Q3 2024 | 5 | $1.2B | INSM, PCVX, GERN, KROS, SMMT |
| Q2 2024 | 9 | $859.5M | CYTK, INSM, PCVX, GERN, KROS |
| Q1 2024 | 12 | $751.2M | PCVX, NUVL, KROS, BHVN, ALPN |